Demyelinating Diseases  >>  amiselimod (MT 1303)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
NCT01742052 / 2012-002470-31: Dose-finding Study of MT-1303

Completed
2
415
Canada, Europe, RoW
MT-1303-Low, MT-1303-Middle, MT-1303-High, Placebo
Mitsubishi Tanabe Pharma Corporation
Relapsing-remitting Multiple Sclerosis
07/14
10/14
NCT01890655 / 2012-002639-27: Extension Study of MT-1303

Completed
2
367
Canada, Europe, RoW
MT-1303-Low, MT-1303-Middle, MT-1303-High
Mitsubishi Tanabe Pharma Corporation
Relapsing-remitting Multiple Sclerosis
03/16
03/16

Download Options